These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23405972)

  • 61. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
    Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC
    Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation.
    D'Aveni M; Aïssi-Rothé L; Venard V; Salmon A; Falenga A; Decot V; Virion JM; Wang Y; Clement L; Latger-Cannard V; Tomowiak C; Stoltz JF; Bordigoni P; Bensoussan D
    Transpl Immunol; 2011 May; 24(4):224-32. PubMed ID: 21440066
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
    Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
    Ashoor IF; Al-Akash S; Kizilbash S; Moudgil A; Puliyanda D; Ranabothu S; Shi Y; Dharnidharka V
    Pediatr Transplant; 2024 May; 28(3):e14743. PubMed ID: 38566336
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
    Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
    J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
    [No Abstract]   [Full Text] [Related]  

  • 67. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
    Hubácek P; Cinek O; Kulich M; Zajac M; Keslová P; Formánková R; Starý J; Sedlácek P
    Cas Lek Cesk; 2006; 145(4):301-6. PubMed ID: 16639931
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
    Faraci M; Caviglia I; Morreale G; Lanino E; Cuzzubbo D; Giardino S; Di Marco E; Cirillo C; Scuderi F; Dallorso S; Terranova P; Moroni C; Castagnola E
    Bone Marrow Transplant; 2010 Jun; 45(6):1052-5. PubMed ID: 19855442
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu L; Zhang X; Feng S
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [An analysis of risk factors and prognosis of Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation].
    Zhang Q; Zou BH; Lou X; Liu H; Zhang B; Chen H
    Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):619-23. PubMed ID: 27480556
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
    Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
    Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
    Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
    Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk factors for post-transplant Epstein-Barr virus events in pediatric recipients of hematopoietic stem cell transplants.
    Enok Bonong PR; Buteau C; Duval M; Lacroix J; Laporte L; Tucci M; Robitaille N; Spinella PC; Cuvelier GDE; Lewis V; Vercauteren S; Alfieri C; Trottier H
    Pediatr Transplant; 2021 Nov; 25(7):e14052. PubMed ID: 34076939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.